GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On September26, 2017, the Board of Directors of Genomic Health,Inc. (the “Company”) adopted the Genomic Health,Inc. Deferred Compensation Plan (the “Plan”). The Plan will be effective as of January1, 2018. The Plan is intended to be an “unfunded” plan and will be maintained by the Company primarily for the purpose of providing deferred compensation to a select group of employees and members of the Board of Directors. Accordingly, the Plan is also intended to be exempt from Sections 201(2), 301(a)(3)and 401(a)(1)of the Employee Retirement Income Security Act of 1974, as amended, and to comply with the requirements of Section409A of the Internal Revenue Code of 1986, as amended. Deferred Compensation under the Plan will consist of elective deferrals, if any, made by Plan participants. Deferrals under the plan will be fully vested at all times. Under the Plan, the Company will provide participants with the opportunity to defer a maximum of 75% of their base salary, bonuses, commercial incentives and Board of Directors fees (or such other percentage that may be prescribed by the Plan administrator). Payment obligations, if any, under the Plan are payable in cash on a date or dates selected by the participant to the terms of the Plan, or upon certain specified events such as termination of employment, death, or disability, subject to change in certain specified circumstances.


About GENOMIC HEALTH,INC. (NASDAQ:GHDX)

Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

An ad to help with our costs